These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 8944206

  • 41. The pathophysiologic basis of efficacy and clinical experience with the new oral antidiabetic agents.
    Rosak C.
    J Diabetes Complications; 2002; 16(1):123-32. PubMed ID: 11872380
    [Abstract] [Full Text] [Related]

  • 42. Glimepiride. A review of its use in the management of type 2 diabetes mellitus.
    Langtry HD, Balfour JA.
    Drugs; 1998 Apr; 55(4):563-84. PubMed ID: 9561345
    [Abstract] [Full Text] [Related]

  • 43. Effect of an alpha-glucosidase inhibitor combined with sulphonylurea treatment on glucose metabolism in patients with non-insulin-dependent diabetes mellitus.
    Okada S, Ishii K, Tanokuchi S, Hamada H, Ichiki K, Ota Z.
    J Int Med Res; 1995 Apr; 23(4):279-83. PubMed ID: 7589771
    [Abstract] [Full Text] [Related]

  • 44. [Analogs of glucagon-like peptide-1 (GLP-1): an old concept as a new treatment of patients with diabetes mellitus type 2].
    Diamant M, Bunck MC, Heine RJ.
    Ned Tijdschr Geneeskd; 2004 Sep 25; 148(39):1912-7. PubMed ID: 15495988
    [Abstract] [Full Text] [Related]

  • 45. The European Association for the Study of Diabetes Annual Meeting, 1998. Treatment of type 2 diabetes and the pathogenesis of complications.
    Bloomgarden ZT.
    Diabetes Care; 1999 Jul 25; 22(7):1209-15. PubMed ID: 10388992
    [No Abstract] [Full Text] [Related]

  • 46. Therapeutic potential of glucagon-like peptide 1 in type 2 diabetes.
    Nauck M.
    Diabet Med; 1996 Sep 25; 13(9 Suppl 5):S39-43. PubMed ID: 8894470
    [Abstract] [Full Text] [Related]

  • 47. Glucagon-like peptide-1 structure, function and potential use for NIDDM.
    Gefel D, Barg Y, Zimlichman R.
    Isr J Med Sci; 1997 Oct 25; 33(10):690-5. PubMed ID: 9397146
    [Abstract] [Full Text] [Related]

  • 48. Regulation, perturbation, and correction of metabolic events in pancreatic islets.
    Malaisse WJ.
    Acta Diabetol; 1996 Sep 25; 33(3):173-9. PubMed ID: 8904921
    [Abstract] [Full Text] [Related]

  • 49. Adjunct therapy for type 1 diabetes mellitus.
    Lebovitz HE.
    Nat Rev Endocrinol; 2010 Jun 25; 6(6):326-34. PubMed ID: 20404854
    [Abstract] [Full Text] [Related]

  • 50. Type 2 diabetes: glycemic targets and oral therapies for older patients.
    Lardinois CK.
    Geriatrics; 1998 Nov 25; 53(11):22-3, 27-8, 33-4 passim. PubMed ID: 9824974
    [Abstract] [Full Text] [Related]

  • 51. [Efficacy of combination therapy of alpha-glucosidase inhibitor and insulin sensitizer in patients with type 2 diabetes].
    Kitaoka H.
    Nihon Rinsho; 2002 Sep 25; 60 Suppl 9():464-9. PubMed ID: 12387035
    [No Abstract] [Full Text] [Related]

  • 52. The use of sulphonylureas in the elderly.
    Graal MB, Wolffenbuttel BH.
    Drugs Aging; 1999 Dec 25; 15(6):471-81. PubMed ID: 10641958
    [Abstract] [Full Text] [Related]

  • 53. Oral hypoglycemic agents: insulin secretagogues, alpha-glucosidase inhibitors and insulin sensitizers.
    Raptis SA, Dimitriadis GD.
    Exp Clin Endocrinol Diabetes; 2001 Dec 25; 109 Suppl 2():S265-87. PubMed ID: 11460577
    [Abstract] [Full Text] [Related]

  • 54. Oral pharmacologic management of type 2 diabetes.
    Riddle MC.
    Am Fam Physician; 1999 Dec 25; 60(9):2613-20. PubMed ID: 10605995
    [Abstract] [Full Text] [Related]

  • 55. Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients.
    Seifarth C, Bergmann J, Holst JJ, Ritzel R, Schmiegel W, Nauck MA.
    Diabet Med; 1998 Jun 25; 15(6):485-91. PubMed ID: 9632123
    [Abstract] [Full Text] [Related]

  • 56. [Future targets in the treatment of type 2 diabetes].
    Stingl H, Roden M.
    Wien Klin Wochenschr; 2004 Apr 30; 116(7-8):217-29. PubMed ID: 15143860
    [Abstract] [Full Text] [Related]

  • 57. Effect of linagliptin compared with glimepiride on postprandial glucose metabolism, islet cell function and vascular function parameters in patients with type 2 diabetes mellitus receiving ongoing metformin treatment.
    Forst T, Anastassiadis E, Diessel S, Löffler A, Pfützner A.
    Diabetes Metab Res Rev; 2014 Oct 30; 30(7):582-9. PubMed ID: 24459063
    [Abstract] [Full Text] [Related]

  • 58. [Sulfonylurea and alpha-glucosidase inhibitor].
    Iijima T.
    Nihon Rinsho; 2002 Sep 30; 60 Suppl 9():459-63. PubMed ID: 12387034
    [No Abstract] [Full Text] [Related]

  • 59. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.
    Hücking K, Kostic Z, Pox C, Ritzel R, Holst JJ, Schmiegel W, Nauck MA.
    Diabet Med; 2005 Apr 30; 22(4):470-6. PubMed ID: 15787675
    [Abstract] [Full Text] [Related]

  • 60. GIP as a potential therapeutic agent?
    Meier JJ, Nauck MA.
    Horm Metab Res; 2004 Apr 30; 36(11-12):859-66. PubMed ID: 15655720
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.